Editorial

The Long Road to Understanding Heart Disease in Women

  1. 1Department of Medicine, Emory University School of Medicine
  2. 2Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydnell and Arnold Family Heart, Vascular, and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
3 views
Peer reviewed

Abstract

Heart disease is the leading cause of death among women in the United States, yet for decades the evidence guiding its prevention and treatment came almost entirely from studies of men. The field’ has evolved from an era in which women appeared in the cardiology literature mainly as caregivers to one in which gender disparities are recognized as a central variable in research and care. We describe how epidemiologic data, physician advocacy and federal research policy converged to bring women into clinical trials. The large body of work that followed suggest that many apparent outcome differences reflect differences in baseline risk and management rather than gender itself, and that the gap is narrowing. Persistent disparities in treatment, declining awareness and inequities by race and ethnicity remain. We present emerging priorities for research, clinical practice and public health.

  • cardiovascular disease
  • women's health
  • social determinants of health
Contents

Introduction

For most of the last century, we believed that heart disease belonged to men; the research, the guidelines, and the public health messaging centered around the male experience. Today we know that heart disease is the leading cause of death for women in the United States, and 44% of all women aged 20 and older have some heart disease, compared with 54% of men.1 Despite advances over the last four decades, women still face gaps in prevention, diagnosis, and treatment.

Left out of the research

Until the mid to late twentieth century, many articles on cardiovascular health referred to women only as caregivers to husbands who had heart disease or heart attacks, not as patients affected by cardiovascular disease themselves.2 Few articles acknowledged heart disease in women, and the prevailing view of the time was that estrogen protected premenopausal women from coronary atherosclerosis.3

Because heart disease was considered a male problem, the studies that formed the foundation for contemporary cardiovascular care were largely inclusive of men with little female representation. This continued until the mid-1980s when the Framingham Heart Study first reported sex-specific patterns of heart disease, noting that heart attacks were less likely to be recognized in women and that earlier research had enrolled too few women to assess sex differences at all.4

The evidence of sex disparities was mounting — women fared worse once heart disease struck. A 1991 study of 5,839 consecutive heart attack patients in Israel found an age-adjusted in-hospital death rate of 23.1% for women compared with 15.7% for men, and higher mortality for women at one year as well. Female sex remained an independent predictor of death even after accounting for age, prior heart attack, heart failure and other major prognostic factors, and women with diabetes were at particularly high risk.5 Findings like these made it clear that the evidence drawn from men could not simply be applied to women. Heart disease in women urgently warranted focused studies.

Despite the wake-up call, exclusion became an official policy. In 1977, in the wake of the thalidomide tragedy — thousands of women in Europe and Canada who took the drug during pregnancy gave birth to babies with severe limb deformities — the Food and Drug Administration recommended keeping women of childbearing potential out of Phase I and early Phase II drug trials, even women using contraception.6 The caution left a shortage of data on how drugs affect women, and advocates argued that women should be allowed to decide for themselves whether to take on the risks of research.

Research policy was changing at the same time. See Table 1 for key milestones in bringing women into federally funded research.

Table 1: Timeline of milestones in women’s cardiovascular disease research.

Raising awareness

As the body of research on women’s cardiovascular risks grows, disparities have been identified more clearly. A 1999 American Heart Association and American College of Cardiology statement, the first women-specific recommendations for preventing heart disease,12 highlighted studies showing disparities in management of cardiovascular disease. For example, one study found women were less likely to be referred to cardiac rehabilitation after a heart attack or bypass surgery.13 Specific recommendations provided in this statement include counseling on statin initiation instead of hormone replacement therapy for elevated cholesterol and monitoring for the development of hypertension in women taking oral contraceptives.13

The response was a push to reach women directly to address risk factors and prevention. The NHLBI's The Heart Truth campaign unveiled the Red Dress as the national symbol for women and heart disease, and a year later the AHA launched Go Red for Women alongside women-specific prevention guidelines; the two campaigns debuted in 2003 and 2004.14,15

A changing research landscape

Since the NIH inclusion mandates of the early 1990s, studies of women and heart disease have increased drastically. One analysis identified nearly 15,000 publications on heart attacks in women between 2000 and 2022, with steady growth throughout that period.16 In 2021, the Lancet Commission on women and cardiovascular disease brought together an international panel to summarize the evidence, identify the remaining gaps, and set goals for reducing the burden of cardiovascular disease in women by 2030.17 In 2023, an AHA scientific statement led by Dr. Laxmi Mehta reviewed how cardiovascular risk differs among women of different racial and ethnic groups. It recognized significant progress in reducing cardiovascular events, while concluding that risk assessment for women must go beyond traditional risk factors to include sex-specific factors, mental health conditions such as depression and anxiety, and social determinants such as poverty and access to care.18

This explosion of evidence suggests the outcome gap is narrowing and can be closed. Table 2 outlines seminal research studies and their findings.

Table 2: Landmark Women’s Cardiovascular Disease Studies

Where do we go from here?

The work ahead falls into several clear areas, which are summarized in Figure 1.

Figure 1: Future directions for women’s cardiovascular health

Addressing the equity gap. Black women have the highest rates of high blood pressure, stroke, heart failure and coronary artery disease among U.S. women and have been less likely to be included in clinical studies.32 Evidence increasingly identifies socioeconomic contributors to cardiovascular risk, including structural racism and social determinants such as limited access to care, which add stress and raise cardiovascular risk. Addressing this gap should involve expanding the representation of Black and Hispanic women in clinical trials, analyzing results by gender, race, and ethnicity, inclusive of transgender and gender-diverse individuals, and improving accessibility of clinical research.  The RECHARGE trial is the first clinical trial in the US to compare outcomes of coronary artery bypass graft versus percutaneous coronary intervention in women and Black and Hispanic populations. The trial is sponsored by the Patient-Centered Outcomes Research Institute (PCORI), an organization created to support research initiatives that engage patients and caregivers in all aspects of the study process.33

Diversifying cardiology. Dr. Gina Lundberg of the Emory Woman's Heart Center argues that too few women, and especially too few women of color, are entering cardiology, and that a woman caring for a woman may listen differently. Dr. Jennifer Mieres adds that patients who see themselves reflected in their care team tend to trust more, share more and follow treatment plans more closely. Data shows that while still underrepresented, the percentage of women cardiovascular trainees and Black or Hispanic cardiovascular trainees has increased significantly in the last ~15 years (17.6% to 25.5% for women and 8.6% to 13.8% for Black or Hispanic trainees).34

Embracing new tools. Artificial intelligence, telehealth, and digital platforms are new and likely important approaches in advancing equity and identifying targets for change. Along with newer statistical methods for predicting risk, these tools could help flag women at risk, bring prevention to women who can't easily reach a cardiologist, and reduce the human biases that lead to missed diagnoses.

The history of women's heart disease continues to evolve, from being viewed as caregivers to an ailing male population with heart disease to championing programs devoted to equitable care and improved representation in clinical trials. Four decades of research are narrowing many of the gaps first documented in the Framingham Study. Progress can also reverse. Women's awareness that heart disease is their leading killer rose to 65% by 2009, then fell back to 44% by 2019.35 Change is possible, but it takes advocates to sustain it. The next chapter depends on keeping women and minority populations at the table of the science and the conversation.

References

1.         Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2026/03/03 2026;153(9):e275-e906.

2.         Miller CL, Kollauf CR. Evolution of information on women and heart disease 1957-2000: A review of archival records and secular literature. Heart & Lung. 2002/07/01/ 2002;31(4):253-261.

3.         Jackson RH. OESTROGENS AND CORONARY HEART DISEASE. Br Med J. Dec 14 1963;2(5371):1487.

4.         Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. Feb 1986;111(2):383-390.

5.         Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. Circulation. 1991/02/01 1991;83(2):484-491.

6.         Levine C. Women and HIV/AIDS Research: The Barriers to Equity. Evaluation Review. 1990/10/01 1990;14(5):447-463.

7.         Women's Health : Report Of The Public Health Service Task Force On Women's Health Issues. Public Health Rep. 100(1):73-106. 1985;100(1).

8.         Kirschstein RL. Research on women's health. Am J Public Health. Mar 1991;81(3):291-293.

9.         Healy B. Women's health, public welfare. Jama. Jul 24-31 1991;266(4):566-568.

10.       Wenger NK, Speroff L, Packard B. Cardiovascular Health and Disease in Women. New England Journal of Medicine. 1993;329(4):247-256.

11.       Kennedy EMS-rC-. National Institutes of Health Revitalization Act of 1993. 1993; https://www.congress.gov/bill/103rd-congress/senate-bill/1. Accessed November 1, 2026.

12.       Mosca L, Grundy SM, Judelson D, et al. Guide to Preventive Cardiology for Women. Circulation. 1999/05/11 1999;99(18):2480-2484.

13.       O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation. Aug 1989;80(2):234-244.

14.       Zwas DR. Redressing the Red Dress. Circulation. 2018/02/20 2018;137(8):763-765.

15.       Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. Feb 10 2004;109(5):672-693.

16.       Xu M, Yang F, Shen B, et al. A bibliometric analysis of acute myocardial infarction in women from 2000 to 2022. Front Cardiovasc Med. 2023;10:1090220.

17.       Vogel B, Acevedo M, Appelman Y, et al. The <em>Lancet</em> women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet. 2021;397(10292):2385-2438.

18.       Mehta LS, Velarde GP, Lewey J, et al. Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. Circulation. 2023/05/09 2023;147(19):1471-1487.

19.       Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med. Jul 25 1991;325(4):221-225.

20.       Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. Sep 12 1991;325(11):756-762.

21.       Hochman Judith S, Tamis Jacqueline E, Thompson Trevor D, et al. Sex, Clinical Presentation, and Outcome in Patients with Acute Coronary Syndromes. New England Journal of Medicine.341(4):226-232.

22.       Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. Jul 22 1999;341(4):217-225.

23.       Mosca L, Jones WK, King KB, Ouyang P, Redberg RF, Hill MN. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. American Heart Association Women's Heart Disease and Stroke Campaign Task Force. Arch Fam Med. Jun 2000;9(6):506-515.

24.       Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama. Jul 17 2002;288(3):321-333.

25.       Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937-952.

26.       Ridker Paul M, Cook Nancy R, Lee IM, et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. New England Journal of Medicine.352(13):1293-1304.

27.       Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. Feb 7 2006;47(3 Suppl):S4-s20.

28.       Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. Feb 7 2006;47(3 Suppl):S21-29.

29.       Ridker Paul M, Danielson E, Fonseca Francisco AH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine.359(21):2195-2207.

30.       Bucholz EM, Strait KM, Dreyer RP, et al. Editor's Choice-Sex differences in young patients with acute myocardial infarction: A VIRGO study analysis. Eur Heart J Acute Cardiovasc Care. Oct 2017;6(7):610-622.

31.       Kovacic JC, Reynolds HR, Alasnag M, et al. Acute Coronary Syndromes in Premenopausal Women: A Scientific Statement From the American Heart Association. Circulation. 2026/02/17 2026;153(7):e89-e108.

32.       Hines AL, Zare H, Roland J Thorpe J. Racial Disparities in Hypertension Among Young, Black and White Women. Journal of General Internal Medicine. 2021 Sep 1;37(8).

33.       Redfors B, Spertus JA, Yancy C, Masterson-Creber R, Stone GW, Gaudino MFL. Expanding revascularization trials to women and underserved minorities and shifting to patient-centered outcomes: RECHARGE trials program. Curr Opin Cardiol. Nov 1 2024;39(6):478-484.

34.       Snow SC, Alhanti B, Douglas PS. Recruiting a Diverse Cardiology Physician Workforce. JAMA Cardiol. Mar 1 2024;9(3):290-294.

35.       Cushman M, Shay CM, Howard VJ, et al. Ten-Year Differences in Women's Awareness Related to Coronary Heart Disease: Results of the 2019 American Heart Association National Survey: A Special Report From the American Heart Association. Circulation. Feb 16 2021;143(7):e239-e248.

Disclosures

The authors declare no relevant financial, professional, institutional, or other relationships.

AI-assisted, human reviewedAI helped with the content, but the human substantially created, edited, or directed the final result and reviewed it before publishing.

This is not medical advice. Check with a doctor before acting on anything you read here.

Cite this article

Gabriela Maria Diaz, DO, Jacqueline E. Tamis-Holland, MD. The Long Road to Understanding Heart Disease in Women. Vitahash. 2026. https://doi.org/10.68919/vitahash.2026.00013 STAMP-2026-1121-U422WPBT

0 comments

You need an account to comment. Sign in or sign up.

Loading comments.